Synact announced today that the company expects to present interim data from its Phase IIa study in rheumatoid arthritis (RA) during Q2 2020 instead of in Q1 2020 as previously communicated. Despite this, we keep our Base case valuation at SEK 17 and continue to see an attractive case at current price levels.